US2014113290A1PendingUtilityA1

Aberrant methylation of c6orf150 dna sequences in human colorectal cancer

Assignee: UNIV TEXASPriority: Aug 27, 2009Filed: Dec 17, 2013Published: Apr 24, 2014
Est. expiryAug 27, 2029(~3.1 yrs left)· nominal 20-yr term from priority
G01N 33/57535G01N 2500/10C12Q 2600/136G01N 2800/56C12Q 2600/154C12Q 1/6886C12Q 2600/156
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This application describes methods and compositions for detecting and treating C6Orf150-associated neoplasia. Differential methylation of the C6Orf150 nucleotide sequences has been observed in C6Orf150-associated neoplasia such as colon neoplasia.

Claims

exact text as granted — not AI-modified
1 - 29 . (canceled) 
     
     
         30 . A method for detecting colon cancer, comprising:
 a) obtaining a sample from a patient; and   b) assaying said sample for the presence of methylation of nucleotide sequences within at least two genes selected from: C6Orf150, SLC5A8, HLTF, p16, and hMLH1;   wherein methylation of nucleotide sequences within any of the genes is indicative of colon cancer.   
     
     
         31 . The method of  claim 30 , wherein the sample is a bodily fluid selected from the group consisting of blood, serum, plasma, a blood-derived fraction, stool, urine, and a colonic effluent. 
     
     
         32 . The method of  claim 31 , wherein the bodily fluid is obtained from a subject suspected of having or is known to have colon cancer. 
     
     
         33 - 53 . (canceled)

Join the waitlist — get patent alerts

Track US2014113290A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.